NC762 

NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

NC762 (0.01-100 nM) binds to B7-H4 with an EC₅₀ of 1.12 nM in 624Mel.B7H4 cells and EC₅₀ of 0.976 nM in SKBR3 cells ^[2].
NC762 (0.1 ng/mL-100 μg/mL) binds to B7-H4 in human 293T cells but not mouse B7-H4^[2].
NC762 (0.1 pM-1000 nM) suggests increased binding to CD16a compared to V5.hlgG₁^[2].
NC762 (0.1-100 pM, 5 h) exhibits ADCC activity in 624Mel.B7H4 and SKBR3 cultured with effector Jurkat reporter cell line^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NC762 (1-30 mg/kg, i.p., Q7D for 4 doses) reduces tumor volume dose-dependently in NSG mice subcutaneous inoculated with 1E06 624Mel.hB7H4 cells and 3E05 human PBMCs^[2].
NC762 (10 mg/kg, i.p., Q4D for 7 doses) reduces anti-B7H4 mediated tumor growth with NK cell contribution and extends survival in NSG mice model subcutaneous inoculated with 1E06 624Mel.hB7H4 cells mixed with either 1E06 total or NK-cell depleted PBMCs^[2].
NC762 (10 mg/kg, i.p., Q7D for 4 doses) restricts tumor growth in NSG mice model subcutaneous inoculated with 1E06 624Mel.hB7H4 cells in either absence of PBMCs or the presence of human T cells^[2].
NC762 (10 mg/kg, i.p., Q7D for 4 doses) inhibits tumor growth with similar activity as a mutant of NC762 that has a low Fc affinity in NSG mice subcutaneous inoculated with 1E06 624Mel.hB7H4 cells, suggesting an ADCC-independent mechanism of tumor growth restriction^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Myint, Han, et al. "748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors." (2022).

  [2]. Kristina Archer, et al. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies. Cancer Res 1 July 2021; 81 (13_Supplement): 3193.